Loading clinical trials...
Loading clinical trials...
This is a Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study of ISIS 681257 Subcutaneous Injections in Male And Female Subjects with Normal and Impaired Renal ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Akcea Therapeutics
Collaborators
NCT07154901 · Renal Impairment
NCT07165015 · Renal Impairment, Healthy, and more
NCT06693765 · Renal Impairment, End-stage Kidney Disease, and more
NCT06352411 · Healthy, Renal Impairment
NCT06835127 · Renal Impairment, Limb Ischemia, Critical
Clinical Site
Orlando, Florida
Clinical Site
Knoxville, Tennessee
Clinical Site
Québec
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions